These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36345897)

  • 21. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.
    Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K
    Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies.
    Garanto A
    Adv Exp Med Biol; 2019; 1185():71-77. PubMed ID: 31884591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.
    Kessel L; Christensen UC; Klemp K
    Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical Aspects in Gene Therapy for Inherited Retinal Diseases.
    Fischer MD; Bartz-Schmidt KU; Dimopoulos S; Herrmann P; Gerhardt M; Holz FG; Priglinger S
    Klin Monbl Augenheilkd; 2021 Mar; 238(3):267-271. PubMed ID: 33618387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Molecular exploration of the R91W (RPE65 gene) in Tunisian patients with early onset retinal dystrophy and early onset retinitis pigmentosa].
    Chouchene I; Largueche L; Derouiche K; Mabrouk S; Abdelhak S; El Matri L
    Tunis Med; 2015 Jul; 93(7):445-8. PubMed ID: 26757501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.
    Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA
    JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retinal dystrophies and gene therapy.
    Sundaram V; Moore AT; Ali RR; Bainbridge JW
    Eur J Pediatr; 2012 May; 171(5):757-65. PubMed ID: 22080959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions.
    Kumaran N; Moore AT; Weleber RG; Michaelides M
    Br J Ophthalmol; 2017 Sep; 101(9):1147-1154. PubMed ID: 28689169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
    Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
    Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voretigene neparvovec-rzyl for treatment of
    Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
    Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular genetic analysis using targeted NGS analysis of 677 individuals with retinal dystrophy.
    Jespersgaard C; Fang M; Bertelsen M; Dang X; Jensen H; Chen Y; Bech N; Dai L; Rosenberg T; Zhang J; Møller LB; Tümer Z; Brøndum-Nielsen K; Grønskov K
    Sci Rep; 2019 Feb; 9(1):1219. PubMed ID: 30718709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.
    Farmer C; Bullement A; Packman D; Long L; Robinson S; Nikram E; Hatswell AJ; Melendez-Torres GJ; Crathorne L
    Pharmacoeconomics; 2020 Dec; 38(12):1309-1318. PubMed ID: 32875526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gene therapy in ophthalmology].
    Priglinger CS; Gerhardt MJ; Rudolph G; Priglinger SG; Michalakis S
    Ophthalmologie; 2023 Aug; 120(8):867-882. PubMed ID: 37418021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials.
    Daich Varela M; Cabral de Guimaraes TA; Georgiou M; Michaelides M
    Br J Ophthalmol; 2022 Apr; 106(4):445-451. PubMed ID: 33712480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.
    Bennett J; Maguire AM
    Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect.
    Leroy BP; Fischer MD; Flannery JG; MacLaren RE; Dalkara D; Scholl HPN; Chung DC; Spera C; Viriato D; Banhazi J
    Ophthalmic Res; 2023; 66(1):179-196. PubMed ID: 36103843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.
    Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN;
    Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.
    Weng CY
    Ophthalmol Retina; 2019 May; 3(5):450. PubMed ID: 31044739
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.